U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine

PERTH, Australia - U.S. FDA's Center for Biologics issued an Untitled Letter June 24 to CSL Biotherapies for deviations from current good manufacturing practices at its manufacturing plant in the Australian state of Victoria